Sinus of valsalva aneurysm repair in an octogenarian using CorMatrix ECM®

Juan A. Siordia,* Christopher Piercecchi, Todd R. Golden, Samata R. Paidy, Sreekumar Subramanian

Department of Surgery, University of Arizona Medical Center, University of Arizona, Tucson, AZ, United States

Received: July 17, 2015           Accepted: February 17, 2016
DOI: 10.5430/css.v2n2p6           Online Published: February 19, 2016
URL: http://dx.doi.org/10.5430/css.v2n2p6

ABSTRACT

Introduction: Unruptured sinus of Valsalva aneurysms are surgically treated after change in clinical presentation or increased size on serial echocardiography. Prostheses such as Dacron grafts and Gortex are notably used, but use of CorMatrix has not previously been reported. The following case presents the first reported use of CorMatrix for sinus of Valsalva repair.

Presentation of case: An 84-year-old male presented with a 6.3 cm right sinus of Valsalva aneurysm seen with echocardiography. Surgical sinus of Valsalva repair involved inserting BioGlue within the aneurysm and closing the defect with CorMatrix. Two-month follow-up showed no significant postoperative complications.

Discussion: The presented case reports the first use of CorMatrix for sinus of Valsalva repair and represents the oldest patient in the world to undergo this surgery. Sinus of Valsalva aneurysms are asymptomatic in 25% of cases and are incidentally found with echocardiography. Although survival in elderly patients specifically is unknown, postoperative survival overall is 88% at 20 years. CorMatrix is commonly used for structural heart defect repairs, but has not been described for sinus of Valsalva repairs.

Conclusions: CorMatrix presents as a suitable prosthesis for sinus of Valsalva aneurysm repair.

Key Words: Sinus of valsalva aneurysm, Surgical repair, Cardiac surgery, CorMatrix

1. INTRODUCTION

A sinus of Valsalva aneurysm is a rare, most often congenital condition defined as a dilatation of at least one of the sinuses formed by the aortic leaflets within the aortic root—most commonly from the right sinus of Valsalva (with the non-coronary and left coronary sinus less often respectively).[1] The upper limit of normal for sinus diameter in men is 4.0 cm and 3.6 cm in women.[2] Sinus of Valsalva aneurysm is often associated with other congenital conditions, most commonly ventricular septal defect, in 30%-60% of patients, while aortic insufficiency and bicuspid aortic valve are each observed in less than a third and less than a tenth of patients.[3–5] Although most commonly congenital, sinus of Valsalva aneurysm may also be acquired following deceleration trauma, or due to infectious (e.g. bacterial endocarditis, syphilitic aortitis, and tuberculosis) or degenerative disease. The incidence of sinus of Valsalva aneurysm is < 0.1% of the general population and they comprise 0.1% to 3.5% of all congenital cardiac defects.[4,6] Additionally they are much more common in males (4:1) and in Eastern and Asian countries compared to Western countries (5:1).[4,7–10] Unruptured sinus of Valsalva aneurysms are most often asymptomatic and are usually found by routine 2-dimensional echocardiography.[11] Most reported cases arise from a rupture of the aneurysm, producing symptoms including dyspnea, edema, and orthopnea.[12] The mean survival for patients with untreated ruptured sinus of Valsalva aneurysm is 1-2 years.[7,13] Early surgical intervention via patch closure is the preferred

*Correspondence: Juan A. Siordia; Email: jas@email.arizona.edu; Address: 329 N. Norris Ave., Tucson, Arizona, 85719, United States.
treatment for congenital cases.

Elderly patients that present with sinus of Valsalva aneurysms are frequently rejected for aggressive surgical treatment due to safety risks and ethical issues. Most are discharged to hospice care or an intensive care environment after managing heart failure symptoms. Aggressive intervention, if performed correctly, can still provide the favorable solution.

This case also involved the use of extracellular matrix developed by CorMatrix (CorMatrix Cardiovascular Inc., Alpharetta, Georgia) for patch closure. The matrix is bioengineered as an acellular porcine extracellular matrix harvested from the small intestine submucosa. The product was used to shunt the aneurysmal defect containing thrombi.

2. CASE PRESENTATION

An 84-year-old male presented with an asymptomatic right sinus of Valsalva aneurysm measuring 6.3 cm in diameter. This was discovered on echocardiographic evaluation of a cardiac murmur and associated with a normal EKG. Past medical history was significant for aortic insufficiency along with coronary artery disease involving the posterior descending artery. Transesophageal echocardiography (see Figure 1) and cardiac catheterization revealed a large right sinus of Valsalva aneurysm. These findings justified cardiac surgical intervention.

![Figure 1. Transesophageal echocardiography presenting a > 4.5 cm right sinus of valsalva aneurysm (A). Moderate aortic regurgitation was also noted during this study.](image1)

Via a median sternotomy, the May 2012 procedure included exclusion of this aneurysm using a sheet of CorMatrix ECM, suspension of the commissure between the right and non-coronary sinuses, and saphenous vein graft bypass to the right coronary artery. The CorMatrix was secured from the interface of the sinus superiorly to the top of the aneurysm, excluding the sinus of Valsalva aneurysm from circulation - this effectively encased the aneurysmal section of clotted blood. BioGlue (CryoLife, Kennesaw, Georgia) was added within the aneurysm sac to facilitate thrombosis, eliminating external bowing of the repaired section. Postoperative transesophageal echocardiography revealed complete thrombosis of the aneurysm sac (see Figure 2) and postoperative day 5 echocardiography demonstrated normal left ventricular size (EF 60%-69%) with the sinus of Valsalva mildly dilated, at 3.8 cm - 4.4 cm.

![Figure 2. Post-operative echocardiogram status-post sinus of vallasva aneurysm repair with CorMatrix. Dilated right sinus of vallasva aneurysm at ~ 4 cm filled with thrombi and BioGlue (A). Sinus of vallasva aneurysm bulging into the right ventricular outflow tract. Moderate valvular aortic regurgitation also measured (B).](image2)

Following an uncomplicated hospital course, the patient was discharged on postoperative day 5. Apart from continuing his previous daily medication regimen (Lorsartan 100 mg, Finasteride 1.25 mg, Aspirin 81 mg), upon discharge his Lorsartan was cut in half to 50 mg daily and both metoprolol 12.5 mg b.i.d. and docusate 100 mg b.i.d. were added. The patient remained asymptomatic at 1-month and 2-month follow-up and was followed by his community physician.

3. DISCUSSION

Sinus of Valsalva aneurysm arise from incomplete fusion of the aortic media elastin layer and the aortic annulus fibrosa. Initial pathophysiology involves local turbulence and eventual formation of an aneurysmal sac. Twenty-five percent of sinus of Valsalva aneurysms are clinically asymptomatic and detected incidentally via echocardiography. Unruptured aneurysms rarely may cause symptoms via obstruction of the right ventricular outflow tract. Rupture typically leads to large left-to-right shunts and severe congestive heart failure which are commonly treated surgically, although a percutaneous approach is becoming more widely adopted only if
A study involving a 33-year single center experience found with anticoagulation and close follow-up including MRI or echocardiography monitoring. Successful surgical repair was first reported in 1957 and is recommended when the sinus grows to > 50% larger than the average size of the other two sinuses, compresses surrounding chambers or origin of the main coronary arteries, increases in consecutive echocardiograms (> 0.5 cm/year) or presents incidentally during cardiac surgery. In order to avoid complications associated with aneurysm enlargement or endocarditis, early surgical repair has been recommended especially since this surgery is associated with low morbidity and mortality, however this has not been established in elderly patients.

A study involving a 33-year single center experience found patients undergoing sinus of Valsalva aneurysm repairs were more commonly males (70%) and the average age was 30 years. Hospital course morbidity and mortality was 2% in 2006. A 2014 seven case series with short term results supported CorMatrix for aortic root enlargement. Prostheses such as Dacron® (Terumo, Somerset, New Jersey) or Gore-TEX® (W. L. Gore and Associates, Newark, Delaware) are effective repair mediums for sinus of Valsalva aneurysms, but the advantage of CorMatrix is its ability to transition histologically into aortic tissue. Outcomes comparing the prostheses in terms of sinus of Valsalva repair have not been performed; this case is the first use of CorMatrix for sinus of Valsalva repair. No complications have occurred after 2-month follow-up in the presented case, suggesting the value of the extracellular matrix as a potential suitable candidate for congenital sinuses of Valsalva aneurysm repair. Further studies are required to definitively compare the prostheses for sinus of Valsalva aneurysm repair.

**CONFLICTS OF INTEREST Disclosure**
The authors declare that they have no conflict of interest.

## References


